A Phase 1, Open-Label, Prospective, Dose-finding Clinical Trial for Evaluation of Safety and Tolerability of Intramuscular Injections of CLZ-2002 for the Treatment of Subjects With Charcot-Marie-Tooth Type 1(CMT 1)
Latest Information Update: 21 Feb 2025
At a glance
- Drugs CLZ-2002 (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions; First in man
- Sponsors Cellatoz Therapeutics
Most Recent Events
- 17 Feb 2025 Status changed from active, no longer recruiting to completed.
- 03 Apr 2024 Planned End Date changed from 30 Nov 2024 to 30 Jul 2024.
- 03 Apr 2024 Planned primary completion date changed from 30 May 2024 to 30 Jul 2024.